• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
CHEN Wenting, LIU Jun. Advances in research on immune checkpoint and its inhibitors in glioma[J]. Journal of China Pharmaceutical University, 2021, 52(1): 104-112. DOI: 10.11665/j.issn.1000-5048.20210115
Citation: CHEN Wenting, LIU Jun. Advances in research on immune checkpoint and its inhibitors in glioma[J]. Journal of China Pharmaceutical University, 2021, 52(1): 104-112. DOI: 10.11665/j.issn.1000-5048.20210115
shu

Advances in research on immune checkpoint and its inhibitors in glioma

  • Center of New Drug Screening, China Pharmaceutical University, Nanjing 210009, China

Funds: This study was supported by the National Natural Science Foundation of China (No.81973361)
More Information
  • Received Date: September 21, 2020
  • Revised Date: December 13, 2020
    Graphical Abstract
    • Abstract
  • Conventional treatment of glioma has not significantly improved the prognosis of patients, so people pay more attention to the potential of immuno-checkpoint inhibitors in the treatment of glioma. This article reviews the expression and mechanism of some negative immune checkpoints in gliomas, such as programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), cytotoxic T lymphocyte antigen-4 (CTLA-4), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte-activation gene-3 (LAG-3), T cellimmunoreceptor with Ig and ITIM domains (TIGIT), B7-H4 and V-domain immunoglobulin suppressor of T-cell activation (VISTA), as well as progress of immune checkpoint inhibitors in clinical research, with a prospect of their future in immunotherapy.
    • FullText(HTML)
    • References (65)
  • [1]
    . Nat Rev Neurol， 2015， 11（9）： 504-514.
    [2]
    Lim M， Xia YX， Bettegowda C， et al. Current state of immunotherapy for glioblastoma［J］. Nat Rev Clin Oncol， 2018， 15（7）： 422-442.
    [3]
    Hung AL， Garzon-Muvdi T， Lim M. Biomarkers and immunotherapeutic targets in glioblastoma［J］. World Neurosurg， 2017， 102： 494-506.
    [4]
    Sharma P， Allison JP. The future of immune checkpoint therapy［J］. Science， 2015， 348（6230）： 56-61.
    [5]
    Kelly PN. The cancer immunotherapy revolution［J］. Science， 2018， 359（6382）： 1344-1345.
    [6]
    Ribas A， Wolchok JD. Cancer immunotherapy using checkpoint blockade［J］. Science， 2018， 359（6382）： 1350-1355.
    [7]
    Sharma P， Allison JP. Immune checkpoint targeting in cancer therapy： toward combination strategies with curative potential［J］. Cell， 2015， 161（2）： 205-214.
    [8]
    Chen LP， Han X. Anti-PD-1/PD-L1 therapy of human cancer： past， present， and future［J］. J Clin Invest， 2015， 125（9）： 3384-3391.
    [9]
    Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway［J］. N Engl J Med， 2016， 375（18）： 1767-1778.
    [10]
    Yao Y， Tao R， Wang XM， et al. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells［J］. Neuro Oncol， 2009， 11（6）： 757-766.
    [11]
    Heiland DH， Haaker G， Delev D， et al. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme［J］. Oncotarget， 2017， 8（26）： 42214-42225.
    [12]
    Berghoff AS， Kiesel B， Widhalm G， et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma［J］. Neuro Oncol， 2015， 17（8）： 1064-1075.
    [13]
    Nduom EK， Wei J， Yaghi NK， et al. PD-L1 expression and prognostic impact in glioblastoma［J］. Neuro Oncol， 2016， 18（2）： 195-205.
    [14]
    Bloch O， Crane CA， Kaur R， et al. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages［J］. Clin Cancer Res， 2013， 19（12）： 3165-3175.
    [15]
    Zeng J， See AP， Phallen J， et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas［J］. Int J Radiat Oncol Biol Phys， 2013， 86（2）： 343-349.
    [16]
    Park J， Kim CG， Shim JK， et al. Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma［J］. Oncoimmunology， 2019， 8（1）： e1525243. doi：10.1080/2162402X.2018.1525243.
    [17]
    Antonios JP， Soto H， Everson RG， et al. PD-1 blockade enhances the vaccination-induced immune response in glioma［J］. JCI Insight， 2016， 1（10）： e87059.
    [18]
    Garzon-Muvdi T， Theodros D， Luksik AS， et al. Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma［J］. Oncotarget， 2018， 9（29）： 20681-20697.
    [19]
    Wing K， Onishi Y， Prieto-Martin P， et al. CTLA-4 control over Foxp3+ regulatory T cell function［J］. Science， 2008， 322（5899）： 271-275.
    [20]
    Fong B， Jin R， Wang XY， et al. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells， before and after DC vaccination， can predict survival in GBM patients［J］. PLoS One， 2012， 7（4）： e32614.
    [21]
    Liu FK， Huang J， Liu XM， et al. CTLA-4 correlates with immune and clinical characteristics of glioma［J］. Cancer Cell Int， 2020， 20： 7.
    [22]
    Fecci PE， Ochiai H， Mitchell DA， et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function［J］. Clin Cancer Res， 2007， 13（7）： 2158-2167.
    [23]
    Reardon DA， Gokhale PC， Klein SR， et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic， immunocompetent model［J］. Cancer Immunol Res， 2016， 4（2）： 124-135.
    [24]
    Field CS， Hunn MK， Ferguson PM， et al. Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model［J］. Oncoimmunology， 2017， 7（1）： e1376154.
    [25]
    Das M， Zhu C， Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity［J］. Immunol Rev， 2017， 276（1）： 97-111.
    [26]
    Huang YH， Zhu C， Kondo Y， et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion［J］. Nature， 2015， 517（7534）： 386-390.
    [27]
    Chiba S， Baghdadi M， Akiba H， et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1［J］. Nat Immunol， 2012， 13（9）： 832-842.
    [28]
    Li GZ， Wang Z， Zhang CB， et al. Molecular and clinical characterization of TIM-3 in glioma through 1， 024 samples［J］. Oncoimmunology， 2017， 6（8）： e1328339.
    [29]
    Han S， Feng SZ， Xu LS， et al. Tim-3 on peripheral CD4? and CD8? T cells is involved in the development of glioma［J］. DNA Cell Biol， 2014， 33（4）： 245-250.
    [30]
    Goods BA， Hernandez AL， Lowther DE， et al. Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme［J］. PLoS One， 2017， 12（9）： e0181538.
    [31]
    Kim HS， Chang CY， Yoon HJ， et al. Glial TIM-3 modulates immune responses in the brain tumor microenvironment［J］. Cancer Res， 2020， 80（9）： 1833-1845.
    [32]
    Kim JE， Patel MA， Mangraviti A， et al. Combination therapy with anti-PD-1， anti-TIM-3， and focal radiation results in regression of murine gliomas［J］. Clin Cancer Res， 2017， 23（1）： 124-136.
    [33]
    He YY， Rivard CJ， Rozeboom L， et al. Lymphocyte-activation gene-3， an important immune checkpoint in cancer［J］. Cancer Sci， 2016， 107（9）： 1193-1197.
    [34]
    Grosso JF， Kelleher CC， Harris TJ， et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems［J］. J Clin Invest， 2007， 117（11）： 3383-3392.
    [35]
    Kouo T， Huang LQ， Pucsek AB， et al. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells［J］. Cancer Immunol Res， 2015， 3（4）： 412-423.
    [36]
    Xu F， Liu J， Liu D， et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses［J］. Cancer Res， 2014， 74（13）： 3418-3428.
    [37]
    Wang J， Sanmamed MF， Datar I， et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3［J］. Cell， 2019， 176（1/2）： 334-347.e12.
    [38]
    Liu ZJ， Meng QD， Bartek JJr， et al. Tumor-infiltrating lymphocytes （TILs） from patients with glioma［J］. Oncoimmunology， 2017， 6（2）： e1252894.
    [39]
    Grosso JF， Goldberg MV， Getnet D， et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells［J］. J Immunol， 2009， 182（11）： 6659-6669.
    [40]
    Huang RY， Eppolito C， Lele S， et al. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model［J］. Oncotarget， 2015， 6（29）： 27359-27377.
    [41]
    Harris-Bookman S， Mathios D， Martin AM， et al. Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma［J］. Int J Cancer， 2018， 143（12）： 3201-3208.
    [42]
    Dougall WC， Kurtulus S， Smyth MJ， et al. TIGIT and CD96： new checkpoint receptor targets for cancer immunotherapy［J］. Immunol Rev， 2017， 276（1）： 112-120.
    [43]
    Zhang Q， Bi JC， Zheng XD， et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity［J］. Nat Immunol， 2018， 19（7）： 723-732.
    [44]
    Hung AL， Maxwell R， Theodros D， et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM［J］. Oncoimmunology， 2018， 7（8）： e1466769.
    [45]
    Zang XX， Loke P， Kim J， et al. B7x： a widely expressed B7 family member that inhibits T cell activation［J］. Proc Natl Acad Sci U S A， 2003， 100（18）： 10388-10392.
    [46]
    Wang JY， Wang WP. B7-H4， a promising target for immunotherapy［J］. Cell Immunol， 2020， 347： 104008.
    [47]
    Yao Y， Wang XM， Jin KL， et al. B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells［J］. J Neurooncol， 2008， 89（2）： 121-129.
    [48]
    Yao Y， Ye HX， Qi ZX， et al. B7-H4（B7x）-mediated cross-talk between glioma-initiating cells and macrophages via the IL6/JAK/STAT3 pathway lead to poor prognosis in glioma patients［J］. Clin Cancer Res， 2016， 22（11）： 2778-2790.
    [49]
    Wang L， Rubinstein R， Lines JL， et al. VISTA， a novel mouse Ig superfamily ligand that negatively regulates T cell responses［J］. J Exp Med， 2011， 208（3）： 577-592.
    [50]
    Flies DB， Wang SD， Xu HY， et al. Cutting edge： a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models［J］. J Immunol， 2011， 187（4）： 1537-1541.
    [51]
    Wang JH， Wu GP， Manick B， et al. VSIG-3 as a ligand of VISTA inhibits human T-cell function［J］. Immunology， 2019， 156（1）： 74-85.
    [52]
    Johnston RJ， Su LJ， Pinckney J， et al. VISTA is an acidic pH-selective ligand for PSGL-1［J］. Nature， 2019， 574（7779）： 565-570.
    [53]
    Wang G， Tai RS， Wu YS， et al. The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers［J］. Cytokine Growth Factor Rev， 2020， 52： 1-14.
    [54]
    He XL， Zhou Y， Lu HZ， et al. Prognostic value of VISTA in solid tumours： a systematic review and meta-analysis［J］. Sci Rep， 2020， 10（1）： 2662.
    [55]
    Flies DB， Han X， Higuchi T， et al. Coinhibitory receptor PD-1H preferentially suppresses CD4? T cell-mediated immunity［J］. J Clin Invest， 2014， 124（5）： 1966-1975.
    [56]
    Borggrewe M， Kooistra SM， Noelle RJ， et al. Exploring the VISTA of microglia： immune checkpoints in CNS inflammation［J］. J Mol Med （Berl）， 2020， 98（10）： 1415-1430.
    [57]
    Liu J， Yuan Y， Chen WN， et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses［J］. Proc Natl Acad Sci U S A， 2015， 112（21）： 6682-6687.
    [58]
    Reiss SN， Yerram P， Modelevsky L， et al. Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas［J］. J Immunother Cancer， 2017， 5（1）： 99.
    [59]
    Lukas RV， Rodon J， Becker K， et al. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma［J］. J Neurooncol， 2018， 140（2）： 317-328.
    [60]
    Gorsi HS， Malicki DM， Barsan V， et al. Nivolumab in the treatment of recurrent or refractory pediatric brain tumors： a single institutional experience［J］. J Pediatr Hematol Oncol， 2019， 41（4）： e235-e241.
    [61]
    Carter T， Shaw H， Cohn-Brown D， et al. Ipilimumab and bevacizumab in glioblastoma［J］. Clin Oncol （R Coll Radiol）， 2016， 28（10）： 622-626.
    [62]
    Omuro A， Vlahovic G， Lim M， et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma： results from exploratory phase I cohorts of CheckMate 143［J］. Neuro Oncol， 2018， 20（5）： 674-686.
    [63]
    Reardon DA， Omuro A， Brandes AA， et al. OS10.3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma： CheckMate 143［J］. Neuro Oncol， 2017， 19（suppl 3）： iii21.
    [64]
    Wang X， Guo GC， Guan H， et al. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma［J］. J Exp Clin Cancer Res， 2019， 38（1）： 87.
    [65]
    Reardon DA， Brandes AA， Omuro A， et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma： the CheckMate 143 phase 3 randomized clinical trial［J］. JAMA Oncol， 2020， 6（7）： 1003-1010.
    • Related Articles

  • Related Articles

    [1]ZHU Song, JIANG Jing, LIU Yang, ZOU Wenyu, HU Pengwei, LU Yuting, SONG Min, HANG Taijun. Structural identification of the related substances of lorazepam tablets by LC-MS[J]. Journal of China Pharmaceutical University, 2021, 52(5): 555-565. DOI: 10.11665/j.issn.1000-5048.20210507
    [2]LIANG Fangmei, NI Yueling, WANG Lu, HANG Taijun, SONG Min. Structural identification of the related substances of fusidic acid by LC-MS[J]. Journal of China Pharmaceutical University, 2018, 49(3): 322-332. DOI: 10.11665/j.issn.1000-5048.20180311
    [3]YIN Xiaoya, WANG Cheng, MING Guojun, HANG Taijun. Identification of the related substances in pioglitazone hydrochloride by hyphenated LC-MS techniques[J]. Journal of China Pharmaceutical University, 2017, 48(6): 701-710. DOI: 10.11665/j.issn.1000-5048.20170611
    [4]XU Guijun, LI Zhijun, WANG Qi, TAN Jiejun, SHI Guoshan, QI Wei, LI Di, WANG Youpeng. Isolation and identification of anti-inflammatory constituents from Houttuynia cordata[J]. Journal of China Pharmaceutical University, 2016, 47(3): 294-298. DOI: 10.11665/j.issn.1000-5048.20160308
    [5]CHEN Wenhua, ZOU Limin, ZHANG Fei, ZHANG Liandi, LIAO Mingyi, DING Li. Identification of the related substances in bendamustine hydrochloride[J]. Journal of China Pharmaceutical University, 2015, 46(3): 333-338. DOI: 10.11665/j.issn.1000-5048.20150312
    [6]ZHOU Yongmei, SHI Xianming, MA Lei, ZHANG Sifang. Isolation and identification of Withaphysalins from Physalis minima[J]. Journal of China Pharmaceutical University, 2015, 46(1): 62-65. DOI: 10.11665/j.issn.1000-5048.20150107
    [7]RAO Ya-kun, DING Li, YU Yong. Structural identification of two major impurities in sodium levofolinate[J]. Journal of China Pharmaceutical University, 2012, 43(4): 350-354.
    [8]WANG Ying, YIN Hong-ping, CHEN Tao, WANG Min. Preliminary structural identification and protection on renal cell injury of acidic polysaccharide from Cordyceps sinensis[J]. Journal of China Pharmaceutical University, 2009, 40(6): 559-564.
    [9]Structure Studies of N-(4-chlorobenzyl)-2,3-methylenedio-xyl-9-acetoxyl-10-methoxy-7,8,13,13a-tetrahydro-8H-dibenzo-quinolizine chloride[J]. Journal of China Pharmaceutical University, 2002, (1): 72-74.
    [10]IDENTIFICATION OF SYNTHETIC BY-PRODUCT N-(4-CHLOROBENZOYL)-DICYCLOHEXANYLUREA BY FOURIER TRANSFORM MASS SPECTROMETRY[J]. Journal of China Pharmaceutical University, 1989, (6): 367-369.

Catalog

    Get Citation
    PDF
    XML
    Article views (289) PDF downloads (840) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：302635

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return